Idalia Acosta
General Practice · Miami, FLNPI 1285738716
Payments from drug & device makers
Across 3,433 payments — averaging $3309.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$1.9M
- Boehringer Ingelheim$1M
- Bayer$1M
- AstraZeneca$1M
- Teva Pharmaceuticals USA, Inc.$928K
- Takeda Pharmaceuticals U.S.A., Inc.$846K
- plus $4.6M from 33 others
Across 8 payments — averaging $207.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$1K
- Gilead$474
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$11,360,395 in reported general payments places this provider in the 95th percentile of 6,901 general practice providers in Florida.
Other general practice in Miami
- Jose CardonaMiami$71M
- Armando AcevedoMiami$15.2M
- Jorge AmayaMiami$14.2M
- Hector RodriguezMiami$12.8M
- Lilia Rodriguez AblesMiami$10.7M
- Omar BenitezMiami$6.9M
- Sara LlerenaMiami$6.3M
- Ana AcostaMiami$6.3M
- Gil Fernandez-YeraMiami$4.9M
- Manuel FernandezMiami$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.